buy

Heat Biologics Inc. buy melinda

Heat Biologics Inc.

Startpreis

8,97 €

/ 50%

Kursziel

22.01.19

Rendite (%)

Endpreis

8,59 €

Zusammenfassung

Diese Einschätzung wurde am mit einem Endkurs von 8,59 € beendet. Einen leichten Verlust von verzeichnete die BUY Einschätzung von melinda. melinda hat 50% Zuversicht bei dieser Einschätzung

Finanztrends

Rendite ohne Dividenden (%)

Name	1W	1M	1J	3J
Heat Biologics Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Kommentare von melinda zu dieser Einschätzung

In der Diskussion Heat Biologics Inc. diskutieren

Einschätzung Buy

Rendite (%)

Kursziel 1,80

Veränderung

Endet am

SecteurRecherche biotechnologique et médicale

Métier

Operates as a clinical stage biopharmaceutical company with interest in the development of novel allogeneic drugs

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.

The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.

Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.

The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.

Nombre d'employés : 19 personnes.

melinda